ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO879

Identification and Validation of Differentially Expressed Urinary Exosomal MicroRNAs in Type 2 Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Zang, Jinnan, Queen’s University Belfast, Belfast, United Kingdom
  • Simpson, David A., Queen’s University Belfast, Belfast, United Kingdom
  • Maxwell, Alexander P., Queen’s University Belfast, Belfast, United Kingdom
  • McKay, Gareth J., Queen’s University Belfast, Belfast, United Kingdom
Background

There is a need for improved biomarkers for the early detection of diabetic kidney disease (DKD). MicroRNAs (miRNAs) are short, non-coding regulatory RNA molecules commonly found in urinary exosomes that may be differentially expressed during renal dysfunction. We evaluated urinary exosomal miRNA expression in type 2 DKD (T2DKD).

Methods

87 previously reported human urinary exosomal miRNAs were profiled (Qiagen Human Urine Exosome Focus miRNA Panel) to identify differentially expressed miRNAs in a discovery cohort of patients with T2DKD (n= 14) and individuals with T2D and normal renal function, matched by age and gender (n= 15). Differentially expressed target miRNAs were validated in a second cohort of patients with T2DKD (n= 22) or no diabetes and poor renal function (n=18), and control subjects with T2D and normal renal function (n= 22).

Results

Quantitative expression profiles were normalised according to the NormFinder algorithm. Urinary miR-21-5p, let-7e-5p and miR-23b-3p were significantly upregulated in T2DKD cases compared to T2D controls with good renal function (P<0.05). Conversely, miR-30b-5p and miR-125b-5p expression were significantly lower in T2DKD cases compared to T2D controls (P<0.05). In a logistic regression analysis adjusted for age, sex and mean arterial blood pressure, only miR-21-5p remained significantly associated with T2DKD (odds ratio=3.28, confidence intervals: 1.14 – 9.43; P=0.03). Independent validation in the replication cohort confirmed up-regulation of miR-21-5p expression in T2DKD (2.13-fold, p<0.01) and also in patients without diabetes and poor renal function (1.73-fold, p<0.05). In contrast, miR-30b-5p was downregulated in T2DKD (1.22-fold, p<0.01) and in patients without diabetes and poor renal function (1.52-fold, p<0.005).

Conclusion

Our data identified differential expression of miR-21-5p and miR-30b-5p in individuals with poor renal function, although further clarification to determine if these are associated with general mechanisms of renal dysfunction is required.

Funding

  • Government Support - Non-U.S.